NTX-1088, a first-in-class anti-CD155 antibody currently under evaluation in a Phase I clinical trial (NCT05378425), has been reported to enhance immune activation and promote immune-mediated tumor cell killing both in vitro and in vivo.41,42 However, the mechanism by which NTX-1088 regulates TIGIT, CD96, and KIR2DL5A remains unclear, and the antibody concentration used for CD155 blockade in these studies has not been disclosed, making it difficult to fully evaluate its therapeutic efficacy. Here, TIGIT is linked to neoplasm.